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Objectives: To determine how tuberculosis (TB) treatment affects the health-related quality of life
(HRQL) of patients with pulmonary TB and to identify the predictors of favourable TB treatment
outcomes in Baghdad, Iraq.
Methods: The Functional Assessment of Chronic Illness Therapy – Tuberculosis (FACIT-TB), a new TB-
speciﬁc quality of life instrument derived from the internationally recognized FACIT measurement
system for the assessment of HRQL, was administered. The mean total and subscale scores of the FACIT-
TB at baseline, end of the intensive phase, and end of TB treatment were compared.
Results: After the 2-month intensive phase, physical well-being, functional well-being, and the overall
total scores were signiﬁcantly increased (p < 0.01). Furthermore, at completion of TB treatment, there
were signiﬁcant improvements in the overall HRQL as indicated by the FACIT-TB total score and all
subscales, except social and economic well-being and spiritual well-being. In a direct logistic regression
model, only the FACIT-TB total score made a statistically signiﬁcant contribution towards predicting the
likelihood that a patient would have a favourable TB treatment outcome.
Conclusions: Therapeutic intervention had a positive impact on patient HRQL. We conclude that FACIT-
TB is a reliable tool to monitor HRQL during the course of TB treatment.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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The evaluation of therapeutic interventions is no longer limited
to clinical outcomes such as curing diseases, reducing associated
morbidity or symptoms, preventing mortality, and normalizing
biomedical markers that have been measured traditionally, but it is
now also focused on humanistic outcomes such as patient
satisfaction and quality of life (QoL). Hence, health-related quality
of life (HRQL) assessments are being used in direct patient care
processes, clinical trials, program evaluations, and for monitoring
health status in populations.1
Until recently, no psychometrically robust, concise instrument
existed to assess HRQL in patients with tuberculosis (TB) that was of* Corresponding author. Tel.: +60 14 3427583.
E-mail address: jumandujaili@yahoo.com (J.A. Dujaili).
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).practical use in clinical practice and clinical trials.2,3 Therefore, we
developed a multi-dimensional HRQL measure speciﬁc for pulmonary
TB (PTB) patients in Iraq called the Functional Assessment of Chronic
Illness Therapy – Tuberculosis (FACIT-TB). Building on the conceptual
and methodological framework for the assessment of health status
proposed by Cella and colleagues in the USA4 and Aaronson and
colleagues in Europe,5,6 a modular approach was adopted for the
development of this instrument. The intent was to construct a core
questionnaire covering broad domains of QoL, such as physical well-
being, emotional well-being, and social well-being, relevant to a broad
range of patients regardless of their speciﬁc diagnosis, supplemented
by disease and treatment-speciﬁc (i.e. PTB) modules. The core, general
HRQL questionnaire is comprised of the Functional Assessment of
Cancer Therapy – General (FACT-G) items.4 FACT-G was selected
because of its established psychometrics and history in measuring
HRQL symptoms in patients with a variety of chronic illnesses as well
as in the general population.7ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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assessing the impact of TB and TB-associated treatment on patient
HRQL have been conducted in many regions.8–13 However, such
studies were lacking in Iraq. Therefore, the current study was
conducted to determine how TB treatment affects HRQL of patients
with PTB attending the Thoracic and Respiratory Disease Specialist
Centre in Baghdad, Iraq, and to assess the impact of a number of
factors on the likelihood that a patient would have a favourable TB
treatment outcome (i.e., cured or completed treatment).
2. Methods
2.1. Study design, setting, and population
A prospective cohort study was conducted in Baghdad, Iraq
between September 1, 2012 and July 31, 2013, among consecutive
patients with PTB who received treatment at the Thoracic and
Respiratory Disease Specialist Centre, the largest centre for the
diagnosis, treatment, and recording of all new and previously
treated TB cases in Iraq. Patients aged 18 years or older at the time
of PTB diagnosis were included in the study. Patients with any
associated pulmonary diseases such as lung cancer, chronic
obstructive pulmonary disease, and asthma, and other chronic
diseases likely to affect HRQL including diabetes mellitus and
cardiovascular diseases, as well as hospitalized patients and
patients with underlying immune suppression, were excluded
from the study.
2.2. Quality of life and data collection instruments
A standardized data collection tool was designed to collect the
following data: (1) socio-demographic information including age,
gender, marital status, occupation, and educational level; (2)
environmental variables including habitat and number of house-
hold contacts; (3) ﬁnancial status using a measure rating this as
poor, intermediate, or good; and (4) FACIT-TB questionnaire items.
FACIT-TB is a disease-speciﬁc instrument designed to assess
HRQL in patients diagnosed with PTB and is a part of the FACIT
measurement system.14 We followed a modular approach to
develop the FACIT-TB questionnaire. In this approach, a set of items
assessing QoL issues considered to be relevant and speciﬁc to the
target population of TB patients, but not sufﬁciently covered in the
original FACT-G instrument, were added. Furthermore, the new
subscale structure of the questionnaire was determined through
principal component analysis. It comprises 45 items: 17 items
covering physical well-being (possible score range 0–68), seven
items covering social and economic well-being (possible score
range 0–28), 11 items covering emotional well-being/living with
TB (possible score range 0–44), seven items covering functional
well-being (possible score range 0–28), and three items covering
spiritual well-being (possible score range 0–12). A 5-point Likert-
type scale ranging from 0 (not at all) to 4 (very much) is assigned to
each item. Two different total scores in addition to each individual
subscale score can be obtained (FACT-G total score and FACT-G
plus disease-speciﬁc domain scores). The FACT-G total score
provides a useful summary of overall QoL across a diverse group of
patients. The disease-speciﬁc questionnaire total scores (i.e., FACT-
G plus disease-speciﬁc subscale score) may further reﬁne the
FACT-G summary score. The FACIT-TB total score ranges from 0 to
180, with a higher score corresponding to a better HRQL. Using a
classical psychometric approach, FACIT-TB has demonstrated
excellent reliability, constructs validity, and is a sensitive
instrument to set clinically signiﬁcant differences in longitudinal
studies of TB treatment. The internal consistency estimate was
0.92 and the Cronbach’s alpha coefﬁcients for the FACIT-TB
subscales were uniformly high across all of the subscales, rangingfrom 0.81 to 0.93. Item intra-class correlation coefﬁcients for test–
re-test reliability analysis ranged from 0.72 to 0.92.
2.3. Data collection
When eligible cases were identiﬁed, the FACIT-TB was
administered and completed by the patient him/herself or through
face-to-face interview for those who were illiterate or who had
other difﬁculties. The interviews were conducted by a medical
social worker who was trained prior to the study to standardize the
interview procedure. Subsequently, the interviewer conducted a
structured interview using a data collection form to collect
information on demographics and socio-economic status. The
FACIT-TB HRQL instrument was administered before the respon-
dent was asked about socio-demographic characteristics so that
any discussion did not affect their answers to the questionnaire.
Moreover, the interviews were conducted in a quiet, distrac-
tion-free area at the study centre after informed consent had been
obtained from the individual patient. Additionally, patients were
informed about the aim of the study, the conﬁdentiality of the data
to be collected, and their right to withdraw from the study at any
time. The principal investigator accompanied the interviewer
during the ﬁrst 2 months of the data collection for the purpose of
quality control.
2.4. Statistical analysis
Data were analysed using SPSS version 18 software (SPSS Inc.,
Chicago, IL, USA). Descriptive statistics, such as percentages, mean,
and standard deviation, were calculated. To analyse the signiﬁ-
cance of the continuous data, the independent samples t-test and
Mann–Whitney U-test were applied, as appropriate. Furthermore,
direct logistic regression analysis was performed to assess the
impact of a number of factors on the likelihood that a patient
would have a favourable TB treatment outcome. Statistical
signiﬁcance was set at p < 0.05 for all analyses.
2.5. Ethical considerations
The study protocol, informed consent, and other relevant
documents were reviewed and approved by the Research and
Teaching Aids Division, Training and Development Centre, Minis-
try of Health, Iraq.
3. Results
3.1. Demographic characteristics of the study participants
Three hundred ﬁve participants were recruited consecutively
over a period of 11 months. Participants ranged in age from 18 to
91 years, with a mean age of 41.6 years; 64.6% were male and 28.2%
were illiterate. Furthermore, poor ﬁnancial status was predomi-
nant in our cohort and 50.8% of the patients in the sample were the
breadwinners for their families (Table 1).
3.2. The effect of TB treatment on patient health-related quality of life
To investigate the effect of TB treatment on HRQL of patients
with PTB, the mean of the FACIT-TB total score and its subscale
scores at different stages of treatment were compared. Participants
completed the FACIT-TB questionnaire at baseline, after 2 months
of treatment, and at completion of treatment during their regularly
scheduled follow-up visits. After the 2-month intensive phase,
physical well-being, functional well-being, and FACIT-TB total
scores were signiﬁcantly increased (p < 0.01). Furthermore, there
was a signiﬁcant improvement in overall HRQL as indicated by the
Table 1
Demographic characteristics of patients with pulmonary tuberculosis in Iraq
(N = 305)
Characteristics n (%), or mean  SD
Age, years 41.59  15.43
Sex
Male 197 (64.6)
Female 108 (35.4)
Education status
No formal education 86 (28.2)
Primary school 132 (43.3)
Secondary school 57 (18.7)
University 30 (9.8)
Marital status
Single 71 (23.3)
Married 208 (68.2)
Divorced 4 (1.3)
Widow/widower 22 (7.2)
Number of household members 7.72  4.08
Type of the job
Salaried 60 (19.7)
Waged 18 (5.9)
Self-employed 93 (30.5)
Other 134 (43.9)
Breadwinner
No 150 (49.2)
Yes 155 (50.8)
Financial status
Poor 115 (37.8)
Intermediate 88 (28.9)
Good 102 (33.3)
Smoking status
Never smoker 135 (44.3)
Ever smoker 170 (55.7)
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well-being and spiritual well-being at completion of TB treatment
(Table 2).
3.3. Factors predicting the likelihood of a favourable TB treatment
outcome
Direct logistic regression was performed to assess the impact of
a number of factors on the likelihood that a patient would have a
favourable TB treatment outcome (i.e., cured or completedTable 3
Logistic regression analysis for predicting the likelihood of a favourable TB treatment 
B SE Wa
FACIT-TB total score at baseline 0.019 0.008 6.28
Smoking status 0.222 0.411 0.29
Education status 0.153 0.237 0.41
Financial status 0.044 0.257 0.02
Constant 1.024 0.728 1.97
SE, standard error; OR, odds ratio; 95% CI, 95% conﬁdence interval; FACIT-TB, Function
Table 2
Health-related quality of life determination over the course of tuberculosis treatment 
PWB SEWB EW
At baseline
(n = 136)
31.93  17.62 22.45  5.11 20.
After 2 months of treatment
(n = 136)
38.30  18.04a 22.50  5.27 20.
At completion of treatment
(n = 109)
49.75  14.58a,b 22.57  4.70 28.
EWB/TB, emotional well-being/stigma of having TB; FACIT-TB, Functional Assessment of
well-being; SD, standard deviation; SEWB, social and economic well-being; SpWB, spi
a p < 0.01 compared to score at baseline.
b p < 0.001 compared to score after 2 months of treatment.treatment). Preliminary analysis conﬁrmed that poor educational
status, poor ﬁnancial status, and being a smoker, were independent
determinants of poor HRQL as indicated by the FACIT-TB total
score. Therefore, four independent variables (FACIT-TB total score
at baseline, smoking status, education level, and ﬁnancial status)
were included in the model. The full model containing all
predictors was statistically signiﬁcant (Chi-square (4,
n = 129) = 10.49, p = 0.033), indicating that the model was able
to distinguish between subjects who had favourable TB treatment
outcomes and those who did not. The model as a whole explained
between 7.8% (Cox and Snell R-square) and 11% (Nagelkerke R-
square) of the variance in treatment outcome, and correctly
classiﬁed 69% of the cases. As shown in Table 3, of the independent
variables, only the FACIT-TB total score at baseline made a unique
statistically signiﬁcant contribution to the model. The FACIT-TB
total score at baseline recorded an odds ratio of 1.02. This indicates
that the higher the FACIT-TB total score at baseline, the more likely
that a PTB patient will have a more favourable outcome at the
completion of treatment, while controlling for the other factors in
the model.
4. Discussion
A study of the impact of PTB on various aspects of QoL is
possible by using a disease-speciﬁc HRQL measure. QoL has
become an instrumental outcome measure in clinical research, and
advances have been made in assessing the impact of many diseases
on QoL.10 Different generic HRQL instruments and health utility
measures such as SF-36, SF-12, EQ-5D, WHOQOL-100, and
WHOQOL-BREF, have been used among the studies that have
quantitatively assessed health for patients with TB.2 Although
these instruments have been applied successfully to measure QoL
in patients with TB, perhaps the most signiﬁcant drawback has
been the absence of a widely accepted psychometrically robust TB-
speciﬁc instrument for carrying out such assessments in the
context of TB.2,3,15
In the current study, the gradual increase in physical well-
being, functional well-being, and emotional well-being/TB sub-
scale scores over the course of TB treatment indicates the positive
impact of therapeutic interventions on patient QoL. However, the
emotional well-being/TB subscale score at 2 months of TBoutcome
ld df p-Value OR 95% CI for OR
0 1 0.012 1.020 1.004–1.035
2 1 0.589 0.801 0.358–1.792
6 1 0.519 1.165 0.732–1.856
9 1 0.865 0.957 0.579–1.584
5 1 0.160 0.359
al Assessment of Chronic Illness Therapy – Tuberculosis.
using the FACIT-TB instrument; FACIT-TB total and subscale scores (mean  SD)
B/TB FWB SpWB Total score
54  9.65 12.97  7.17 9.67  2.75 97.56  30.14
78  11.04 13.89  7.67a 9.61  2.80 105.10  30.20a
43  10.50a,b 17.41  6.74a,b 10.56  7.88 128.72  25.28a,b
 Chronic Illness Therapy – Tuberculosis; FWB, functional well-being; PWB, physical
ritual well-being.
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demonstrated that emotional stress is associated with immuno-
logical responsiveness and reactivation of bacillus.16Moreover, the
psychiatric complications as adverse effects of anti-TB medications
are also a matter of concern.17 These factors are viewed as a major
barrier to treatment adherence.17 The risk of treatment default is
high during the ﬁrst 2 months of TB treatment,18 suggesting that
better management of emotional stress could improve treatment
outcomes and will serve as a framework for effective TB control.
International health agencies are considering strategies to inte-
grate mental health services into the existing health systems for
the purpose of increasing responsiveness to patient needs.19
A study carried out to identify how TB affects the QoL of patients
attending two directly observed therapy (DOTS) centres in an
urban area of Delhi using the Hindi version of the WHOQOL-BREF
questionnaire also reported similar results.10 The ﬁnal ﬁndings
demonstrated that there was a signiﬁcant increase in the overall
QoL and in all domains except social after 3 months and at
completion of treatment under DOTS, and that the maximum
improvement was seen in the physical domain followed by the
psychological domain. Moreover, our results are consistent with
the pattern observed in a study conducted in China using the SF-36
questionnaire,8 in which all physical scales including physical
functioning, bodily pain, role-physical, and general health scores
showed a signiﬁcant increase over the course of TB treatment
(p < 0.05), while the improvement in vitality and mental health
was statistically not signiﬁcant.
Previous ﬁndings from the literature support the notion that
there is a signiﬁcant relationship between educational level,
ﬁnancial status and the QoL of patients with TB.20–22 Financial
strains are exacerbated during illness, and this difﬁculty results in
an additional burden for TB patients.23 Moreover, smoking was
signiﬁcantly associated with poor HRQL as indicated by the FACIT-
TB total score. Research demonstrates the negative association
between smoking and HRQL, and the magnitude of this association
is determined by the number of cigarettes smoked.24–26 Further-
more, a study conducted in Malaysia demonstrated that tobacco
smoking is a predictor of poor TB treatment outcomes,27 and that
an integration of DOTS with smoking cessation intervention
potentially improves overall HRQL outcomes among TB patients
who are smokers.28,29 Therefore, smoking cessation interventions
should be offered to all TB patients who are smokers when they are
undergoing TB treatment. The National Tuberculosis Program
(NTP) in Iraq should vigorously integrate tobacco dependence
treatment into the management of TB and should provide capacity
building for healthcare providers caring for TB patients.
A study conducted in Delhi using the DR-12 questionnaire
reported that TB patients who had favourable outcomes at
completion of TB treatment also had higher scores on the DR-12
questionnaire when compared to those who had unfavourable
outcomes.30 This is consistent with our ﬁndings, which demon-
strate that the higher the FACIT-TB total score at baseline, the more
likely it is for the patient to have a favourable outcome at
completion of TB treatment, controlling for other socio-demo-
graphic factors including educational level, ﬁnancial status, and
smoking status. Thus, the FACIT-TB questionnaire could be used for
the comprehensive assessment of HRQL for PTB patients during the
course of TB treatment where the assessment is generally based on
clinical parameters. The evaluation of patients using the FACIT-TB
instrument would also minimize misleading assumptions and
conclusions about the effect of TB treatment on health status as a
result of using generic QoL instruments.31
In conclusion, the newly developed FACIT-TB instrument could
potentially be used to monitor HRQL during the course of TB
treatment. Overall, the current study has managed to contribute
additional information regarding the utility of a disease-speciﬁcQoL instrument as a prognostic variable beyond established
predictors in patients with PTB in Iraq and suggests that such
an instrument could reliably be used to monitor patient QoL
progression. Understanding QoL trends according to speciﬁc
domains will provide a basis for relating patient reported
outcomes with drug therapy and identifying domains that require
other interventions such as social support. Further research is
needed to provide more insight into the predictive validity and
sensitivity of the instrument. Research is also needed to replicate
these ﬁndings and to conﬁrm them in other patient populations.
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